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Abstract
Nanomolar concentrations of Taxol, and other antimitotic agents that interact with microtubules, mediate serine phosphorylation of the
66-kDa Shc isoform (p66shc) in A549 human lung carcinoma cells, 9–18 h after drug treatment. This event coincides with the release of
PARP cleavage fragments that are early indicators of apoptosis. Taxol-induced serine phosphorylation of p66shc results from a MEK-
independent signaling pathway that is activated in A549 cells that have a prolonged or abnormal mitotic phase of the cell cycle [Cancer Res.
60 (2000) 5171]. In contrast, in murine macrophage RAW 264.7 cells, micromolar concentrations of Taxol but not other microtubule-
interacting agents induced serine phosphorylation of p66shc that correlated with the phosphorylation of Raf-1 and extracellular signal-
regulated kinase (ERK1/2), within 15–30 min after Taxol treatment. This event also was induced by lipopolysaccharide (LPS). The MEK-
inhibitor, U0126, that specifically inhibits the activation of ERK also blocked the phosphorylation of p66shc and Raf-1, suggesting that these
processes were MEK-dependent, quite different from that which was observed in A549 cells. Taxol also induced phosphorylation of p38 and
JNK MAP kinases within 8–15 min after drug treatment. It is known that Taxol, but not other microtubule-interacting agents, induces the
production of cytokines, such as tumor necrosis factor alpha (TNF-a) in mouse macrophages. The time course of Taxol-induced TNF-a
expression coincides with that of Taxol-induced p66shc phosphorylation, and U0126 inhibits significantly Taxol-induced TNF-a expression
in RAW 264.7 cells. Our data indicate that the Taxol-induced serine phosphorylation of p66shc in RAW 264.7 cells is microtubule-
independent and may be related to increased TNF-a expression after Taxol and LPS treatment. It is concluded that the mechanisms involved
in Taxol-induced p66shc phosphorylation are distinct in A549 and RAW 264.7 cells. D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Taxol is a clinically effective antitumor drug approved
for the treatment of breast, ovarian, and lung carcinomas [1].
The drug binds specifically to microtubules [2,3] and causes
the formation of stable bundles of microtubules that disrupt
the normal polymerization/depolymerization cycle of the
polymer [4] and suppresses microtubule dynamics [5].
Incubation of cells with Taxol results in the arrest of cells
at metaphase [4] and prolonged exposure of cells to Taxol
induces apoptotic cell death [6–8].
Taxol has additional activities in cells [9,10], particularly
in mouse macrophages, that are distinct from its effects in the
tubulin/microtubule system. It has been demonstrated that
Taxol induces the production of cytokines, such as tumor
necrosis factor alpha (TNF-a) and interleukin 1, enhances
gamma-interferon-induced nitric oxide secretion, and in-
creases tyrosine phosphorylation of proteins, including mito-
gen-activated protein kinase [11–15]. These activities of
Taxol mimic the effects elicited by bacterial lipopolysacchar-
ide (LPS) [16]. Taxol- and LPS-induced activation of murine
macrophages is mediated by heat shock protein 90 [17] and
CD18 has been reported to be a cellular target for Taxol in
these cells [18]. Bcl-2 has been identified as a Taxol-binding
protein, using phage-displayed peptide libraries [19].
The SH2-containing Shc proteins [20] are substrates of
activated tyrosine kinases and have been implicated in a
signaling cascade leading to Ras activation and mitogenesis
[21]. Shc is expressed as three isoforms of 46, 52, and 66
kDa [20]. The 52- and the 46-kDa isoforms share a C-
terminal SH2 domain, a glycine/proline-rich region (CH1),
and an N-terminal phosphotyrosine binding domain. The
predicted amino acid sequence of the 66-kDa is identical to
that of the 52-kDa isoform except it contains an additional
unique N-terminal glycine/proline-rich region, CH2 [22,23].
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In addition to tyrosine phosphorylation of Shc isoforms,
insulin and EGF are able to increase serine/threonine
phosphorylation of p66shc [23,24]. It also has been reported
that p66shc is part of a signal transduction pathway that
regulates stress apoptotic responses and life span in mam-
mals [25]. Recently, it has been demonstrated that treatment
of glomerular mesangial cells with endothelin-1, a vaso-
constrictor peptide, results in serine phosphorylation of
p66shc [26]. Furthermore, Shc has been implicated in
specific steps of metastasis and elevated levels of p66shc
were observed in breast cancer cell lines and primary tumors
with high metastatic potential [27].
We have demonstrated two distinct Taxol-mediated sig-
naling events that are related to Shc proteins. First, micro-
molar concentrations of Taxol induce tyrosine phospho-
rylation of Shc, particularly the 52-kDa isoform and its
association with Grb2, within 10 min in the murine macro-
phage-like cell line RAW 264.7 [28]. Taxol-induced tyrosine
phosphorylation of p52shc was detected by immunoprecipi-
tation of Shc, followed by Western blotting with anti-
phosphotyrosine antibody. Taxol also causes alterations in
the electrophoretic mobility of Raf-1 and extracellular sig-
nal-regulated kinase (ERK1/2) in these cells [28]. Secondly,
nanomolar concentrations of Taxol and other microtubule-
interacting agents mediate serine phosphorylation of the 66-
kDa Shc isoform in the human lung carcinoma cell line
A549, beginning 4 h after drug exposure, and reaching a
maximum at 9–18 h [29]. The domain of Taxol-induced
serine phosphorylation was determined to be in the CNBr
fragment containing residues 2–65 that is unique to the
p66shc isoform [29]. This Taxol-induced serine phosphor-
ylation of p66shc was not inhibited by the MEK inhibitor,
PD98059, although interestingly, a combination of either of
the MEK inhibitors, PD98059, or U0126, plus Taxol
enhanced PARP cleavage [10,29]. It was concluded that
the Taxol-mediated serine phosphorylation of p66shc seen
in A549 cells may have resulted from a MEK-independent
signaling pathway that was activated during an abnormal and
prolonged mitosis [29].
The aim of this study was to determine if serine phos-
phorylation of p66shc occurs in RAW 264.7 cells after
Taxol treatment. We found that LPS or micromolar concen-
trations of Taxol, but not other antimitotic agents, caused
serine phosphorylation of p66shc in these cells within 15–
30 min. Our experimental data indicate that the mechanisms
involved in Taxol-induced serine phosphorylation in RAW
264.7 cells are distinct from those in A549 cells.
2. Materials and methods
2.1. Materials and cells
Monoclonal and polyclonal anti-Shc, and monoclonal
anti-Raf-1 antibodies were purchased from Transduction
Laboratories/PharMingen. Monoclonal anti-phospho-p44/
42 MAP kinase (E10), monoclonal anti-phospho-JNK (G9),
and polyclonal anti-phospho-p38 antibodies were from New
England Biolabs. Protein phosphatase 2A1 (PP2A1) was
purchased from Upstate Biotechnology. The MEK inhibitor,
U0126, was from Promega. The p38 inhibitor, SB203580,
was from Calbiochem. Taxol was obtained from the Drug
Development Branch, National Cancer Institute, Bethesda,
MD. RAW 264.7, a murine macrophage-like cell line, was
maintained in Dulbecco’s modified Eagle’s media containing
10% NCTC-109, 10% fetal bovine serum, 1% nonessential
amino acids, 1% glutamine, and 1% penicillin/streptomycin.
2.2. Preparation of cell lysates and Western blot analysis
Cells were washed three times with phosphate buffered
saline, lysed with boiling buffer containing 1% SDS, 10 mM
Tris–HCl, pH 7.4, boiled for an additional 5 min, passed six
times through a 26 gauge needle, and centrifuged for 5 min
in a microfuge. The supernatants were resolved by SDS-
polyacrylamide gel electrophoresis (SDS-PAGE) and trans-
ferred to nitrocellulose. Western blot analysis was per-
formed as described [28] with ECL reagents.
2.3. Immunoprecipitation and protein phosphatase
treatment
Cell lysates were incubated with polyclonal anti-Shc
antibodies and immunoprecipitation was performed as
described [29]. The immunoprecipitate/protein A agarose
was incubated with 0.25 Ag of protein phosphatase 2A1 in a
buffer containing 25 mM Tris–HCl, pH 7.0, 0.2 mMMnCl2,
1 mM DTT, and 0.1 mg/ml BSA for 1 h at 30 jC. The
reaction was stopped by heating at 100 jC in sample buffer
prior to analysis by SDS-PAGE.
2.4. TNF-a expression
Total RNA was isolated from the cells using Tri Reagent
(Molecular Research Center) following the protocol of the
manufacturer. Twenty micrograms of total RNA was sepa-
rated on a 1.5% agarose gel containing formaldehyde and
transferred to a Genescreen Plus nylon membrane. Blots
were incubated at 60 jC with a 409 base murine TNF-a
probe [30], randomly labeled with [a-32P]dCTP, in hybrid-
ization buffer containing 10% dextran sulfate, 50 mM Tris–
HCl (pH 7.8), 1 M NaCl, and 1% SDS. Desitometry was
done to quantitate the levels of TNF-a expression.
3. Results
3.1. Taxol treatment results in alterations in the
electrophoretic mobility of the 66-kDa Shc isoform (p66shc)
RAW 264.7 cells were treated with 0.1–20 AM Taxol for
30 min. A decreased electrophoretic mobility of p66shc was
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observed in those cells that were incubated with 1 AM or
higher concentrations of the drug. No mobility shift was
seen for either p52shc or p46shc. LPS treatment (1 Ag/ml)
also resulted in a reduction in p66shc mobility (Fig. 1, upper
panel).
Raf-1 activation is associated with hyperphosphorylation
of serine residues, which results in a retardation of Raf-1
electrophoretic mobility on SDS-polyacrylamide gels. Taxol
at a concentration of 1 AM or higher caused a reduction in
mobility of Raf-1 in RAW 264.7 cells (Fig. 1, middle panel).
Taxol also induced the phosphorylation of ERK1/2, as
detected by an antibody specific for the phosphorylated form
of ERK1/2 (Fig. 1, lower panel). LPS also induced phos-
phorylation of Raf-1 and ERK1/2, as described previously
[28]. These results indicate that Taxol-induced electropho-
retic mobility shift of p66shc correlated with phosphoryla-
tion of Raf-1 and ERK1/2, in a dose-dependent manner. The
maximum effects were elicited at 10 AM Taxol.
3.2. Taxol-induced decreased mobility of p66shc results
from serine/threonine phosphorylation
The effect of Taxol on p66shc mobility was monitored
over a period of 4 h. The shift was observed first at 15
min after RAW 264.7 cells were treated with 10 AM
Taxol, reaching a maximum at 30 min and started to
decline 60–90 min after drug treatment. A similar time
course was obtained for Taxol-induced phosphorylation of
Raf-1 and ERK1/2 (Fig. 2A). No electrophoretic mobility
shift of p66shc was observed when RAW 264.7 cells
Fig. 1. Taxol alters the electrophoretic mobility of p66shc. RAW 264.7 cells
were treated with 0.1 to 20 AM Taxol or 1 Ag/ml LPS for 30 min. Lysates
were prepared and Western blot analyses were performed as described in
Materials and methods with monoclonal anti-Shc, anti-Raf-1, or anti-
phospho-ERK1/2 antibodies.
Fig. 2. Taxol-induced electrophoretic mobility shift of p66shc results from serine/threonine phosphorylation. (A) RAW 264.7 cells were treated with 10 AM
Taxol for 8–240 min. Lysates were prepared, and Western blot analyses with monoclonal anti-Shc, anti-Raf-1, or anti-phospho-ERK1/2 antibodies were
performed as described in Materials and methods. (B) Lysates prepared from control cells or cells treated with 10 AM Taxol for 30 min were
immunoprecipitated with polyclonal anti-Shc antibodies, and the immunoprecipitates were treated with or without PP2A1 as described in Materials and
methods, followed by Western blot analysis with monoclonal anti-Shc antibody.
Fig. 3. Taxotere, epothilones, discodermolide, vinblastine, and colchicine
do not alter the electrophoretic mobility of p66shc and Raf-1, or
phosphorylation of ERK1/2. RAW 264.7 cells were treated with 10 AM
of a variety of microtubule interacting agents for 30 min. Cell lysates were
prepared and immunoblotted with monoclonal antibodies against Shc
proteins, Raf-1, or phospho-ERK1/2 as described in Figs. 1 and 2.
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were treated with 10–200 nM Taxol for 16 h (data not
shown).
To determine the nature of the Taxol-induced electropho-
retic mobility shift, cell lysates prepared from control and
Taxol-treated cells were immunoprecipitated with polyclonal
anti-Shc antibody and the immunocomplexes were treated
with serine/threonine protein phosphatases. As shown in Fig.
2B, PP2A1 inhibited the electrophoretic mobility shift of
p66shc, indicating that the Taxol-induced electrophoretic
mobility shift of p66shc was the result of ser/thr phosphor-
ylation. Protein phosphatase 1 and protein phosphatase 2B
had no effect on the phosphorylated form of p66shc at the
concentrations tested (data not shown). PP2A1 also inhibited
the electrophoretic mobility shift of Raf-1 (data not shown).
3.3. Taxol-induced ser/thr phosphorylation of p66shc is
Taxol-specific
A variety of microtubule-interacting agents were used to
compare their effects on the activation of p66shc with that of
Taxol. These compounds included Taxotere, epothilone A
and B, discodermolide, all of which promote polymerization
of stable microtubules, and colchicine and vinblastine, both
of which depolymerize microtubules [31]. Unlike Taxol and
LPS, incubation of RAW 264.7 cells with these drugs (30
min, 10 AM) did not lead to a mobility shift of p66shc, nor
to phosphorylation of Raf-1 or ERK1/2 (Fig. 3). These
results indicate that phosphorylation of p66shc, Raf-1, and
ERK1/2 induced by micromolar concentrations of Taxol are
independent of the interaction of the drugs with micro-
tubules.
3.4. The MEK inhibitor U0126 blocks p66shc
phosphorylation in RAW 264.7 cells
The MEK inhibitor U0126, which inhibits both active
and inactive MEK, clearly inhibited Taxol-induced phos-
phorylation of ERK1/2. It also inhibited Taxol-induced
phosphorylation of p66shc and Raf-1, suggesting that the
activation of ERK1/2 is involved in the Taxol-mediated
phosphorylation of p66shc and Raf-1 (Fig. 4).
3.5. The p38 MAP kinase inhibitor SB203580 does not
block p66shc phosphorylation in RAW 264.7 cells
It has been reported that p38 MAP kinase can be
activated by Taxol or LPS [32]. We also have studied the
effect of Taxol and other microtubule-interacting agents on
the activation of p38 MAP kinase in RAW 264.7 cells. Like
Fig. 4. The MEK inhibitor, U0126, inhibits Taxol-induced phosphorylation
of p66shc, Raf-1, and ERK1/2. RAW 264.7 cells were incubated with 20
AM U0126 for 1 h and then treated with 10 AM Taxol for 30 min in the
presence of the inhibitor. Cell lysates were prepared, and Western blot
analyses were done with monoclonal anti-Shc, anti-Raf-1, or anti-phospho-
ERK1/2 antibodies as described in Figs. 1 and 2.
Fig. 5. The p38 MAP kinase inhibitor, SB203580, does not inhibit Taxol-
induced serine phosphorylation of p66shc in RAW 264.7 cells. (A) Cells
were treated with 10 AM Taxol for 8–240 min. Cell lysates were prepared
and immunoblotted with polyclonal anti-phospho-p38 antibody. (B) Cells
were incubated with 20 AM SB203580 for 1 h and then treated with 10 AM
Taxol for 30 min in the presence of the inhibitor. Cell lysates were prepared
and Western blot analyses were done with polyclonal anti-phospho-p38,
monoclonal anti-Shc, or monoclonal anti-Raf-1 antibodies as described in
Figs. 1 and 2.
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Taxol-induced ERK1/2 activation, maximum p38 activation
was observed when cells were treated with 10 AM Taxol for
30 min (Fig. 5A). However, the phosphorylated p38
decreased to near basal level at 60 min, unlike the time
course observed for Taxol-induced ERK activation, in that
the phosphorylated ERK gradually decreased (see Fig. 2).
Although Taxol elicited the greatest effect on p38 activation
in RAW 264.7 cells, other microtubule-interacting agents,
such as Taxotere, epothilone A and B, vinblastine, colchi-
cine, and discodermolide, also caused a modest effect on
p38 activation (data not shown). Pretreatment of RAW
264.7 cells with the p38 inhibitor, SB203580, which
inhibited Taxol-induced p38 phosphorylation by f 50%,
did not inhibit Taxol-induced phosphorylation of p66shc
and Raf-1 (Fig. 5B), suggesting that activation of p38 may
not be related to p66shc phosphorylation.
3.6. Taxol-induced phosphorylation of JNK is transient in
RAW 264.7 cells
The effect of Taxol on phosphorylation of JNK1/2, a
MAP kinase that is commonly activated in response to
stress, also was monitored over a period of 4 h. Phosphor-
ylation of JNK1/2 was observed first at 8 min after RAW
264.7 cells were treated with 10 AM Taxol, reaching a
maximum at 30 min and decreasing abruptly after 30 min of
drug treatment (Fig. 6). This time course is very similar to
that of Taxol-induced phosphorylation of p38 (see Fig. 5A).
Fig. 6. Taxol-induced phosphorylation of JNK1/2 is transient in RAW 264.7
cells. Cells were treated with 10 AM Taxol for 8–240 min. Cell lysates were
prepared and immunoblotted with monoclonal anti-phospho-JNK antibody
as described in Figs. 1 and 2.
Fig. 7. The MEK inhibitor, U0126, inhibits Taxol-induced TNF-a expression in RAW 264.7 cells. (A) Cells were treated with 10 AM Taxol for 15–60 min.
RNA was prepared and Northern blot analyses were performed using a 409 base TNF-a probe. (B) Quantitation of the levels of TNF-a RNA in cells treated
with 10 AM Taxol for 8 min to 4 h. (C) Cells were incubated with 20 AM U0126 for 1 h and then treated with 10 AM Taxol for 30 or 60 min in the presence of
the inhibitor. RNA was prepared followed by Northern blot analysis, as described in (A). (D) Quantitation of the levels of TNF-a RNA in cells treated with
Taxol in the presence and absence of U0126. One hundred percent represents the level of TNF-a expression in samples treated with Taxol alone.
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3.7. Taxol-induced TNF-a expression is inhibited by U0126
The expression of TNF-a mRNA was increased by
approximately 60-fold after RAW 264.7 cells were treated
with 10 AM Taxol for 30–60 min (Fig. 7A). LPS (1 Ag/ml)
also induced TNF-a expression by approximately 50-fold in
30 min (data not shown). The effect of Taxol on TNF-a
expression was monitored over a period of 4 h (Fig. 7B). A
slight increase in TNF-a was observed 15 min after the cells
were treated with 10 AM Taxol. It reached a maximum at
30–60 min, and started to decline approximately 90 min
after drug treatment This time course is very similar to that
of Taxol-induced phosphorylation of p66shc, Raf-1, and
ERK1/2 (see Fig. 2A). The MEK inhibitor, U0126, inhibited
Taxol-induced TNF-a expression in RAW 264.7 cells by
60% or greater using both Northern blot and RT-PCR
analyses, indicating that activation of ERK1/2 may be
involved in Taxol-mediated TNF-a expression in these cells
(Fig. 7C and D). Surprisingly, U0126 did not inhibit LPS-
induced TNFa expression in these cells by RT-PCR analysis
(data not shown).
4. Discussion
In this report, we have demonstrated in RAW 264.7 cells
that micromolar concentrations of Taxol, but not other
microtubule-interacting agents, induced serine/threonine
phosphorylation of the 66-kDa Shc isoform, 15–30 min
after drug treatment. This alteration coincided with the
Taxol-induced phosphorylation of Raf-1 and ERK1/2, and
an increased expression of TNF-a. Serine/threonine phos-
phorylation of p66shc and Raf-1, and the increased expres-
sion of TNF-a induced by Taxol was inhibited by the MEK
inhibitor U0126, indicating that activation of ERK1/2 is
involved in these processes. These results demonstrate that
the mechanisms involved in Taxol-induced serine/threonine
phosphorylation of p66shc in RAW 264.7 cells are distinct
from those in A549 cells (see Table 1). We previously have
reported that in A549 cells, Taxol-induced serine phosphor-
ylation of p66shc is mediated by nanomolar concentrations
of Taxol and other microtubule-interacting agents, 9–18 h
after drug treatment. Higher concentrations of Taxol (e.g. 20
AM) did not cause this event to occur before 4 h. In these
cells, the MEK inhibitors PD98059 and U0126 did not
inhibit phosphorylation of p66shc and Raf-1, indicating that
the events occurring in A549 cells were microtubule-related
and MEK-independent [29].
It has been demonstrated that although both JNK and p38
MAP kinases are capable of phosphorylating serine 36 of
p66shc in vitro, JNKs are the kinases that phosphorylate
serine 36 in response to UV irradiation in SH-SY5Y cells
[33]. In RAW 264.7 cells, Taxol-induced phosphorylation of
both p38 and JNK1/2 occur prior to the maximal induction
of p66shc phosphorylation by Taxol, suggesting that these
kinases may be responsible for Taxol-induced serine phos-
phorylation of p66shc. However, inhibitor studies using the
p38 inhibitor SB203580 ruled out the possibility that p38
was the kinase in this event (see Fig. 5B). Preliminary
studies using commercially available JNK inhibitor (JNKI1,
Alexis Biochemicals) could not help to determine the role of
JNK in Taxol-induced serine phosphorylation of p66shc,
since JNKI1 did not inhibit Taxol- and LPS-induced JNK
phosphorylation in RAW 264.7 cells.
Studies in RAW 264.7 cells have demonstrated that
transcription regulators, such as krox-24, and enzymes that
modulate proliferation, inflammation, and apoptosis, such as
2V5V-oligoadenylate synthase, cyclooxygenase-2, and chuk,
are induced by Taxol, but not by Taxotere [30]. These
results suggest that taxane-mediated gene induction is
independent of microtubule stabilization and mitotic block-
ade [30]. A study using peritoneal exudate cells from NMRI
outbred mice also demonstrated that, unlike Taxol, epothi-
lone-mediated microtubule stabilization did not trigger
endotoxin-signaling pathways [34]. It has been reported that
LPS and Taxol might share a common receptor/signaling
complex, however, the shared signaling complex is not h-
tubulin [35]. Murine CD18, a surface molecule expressed in
macrophages, which can interact with LPS, has been iden-
tified as a major Taxol-binding protein [18]. Our results
demonstrate that Taxol, but not other microtubule-interact-
ing agents, mediate serine/threonine phosphorylation of
p66shc and activation of Raf-1 and ERK1/2 in RAW
264.7 cells. These microtubule-independent events may be
correlated with a variety of Taxol-mediated gene inductions,
such as TNF-a expression, in macrophages. The relation-
ship between TNFa production and apoptosis has been
examined in RAW 264.7 cells treated with Taxol or Tax-
otere [30]. TNFa production was markedly higher in cells
treated with Taxol compared to those treated with Taxotere.
Taxol-induced TNFa secretion was suppressed by IL-10, an
inhibitor of TNFa transcription. Caspase-3 proteolytic activ-
ity, which reflects the initiation of apoptosis, also was much
higher in cells treated with Taxol than with Taxotere. A
Taxol-induced increase in caspase-3 activity was inhibited
by IL-10. It was concluded that Taxol-induced expression of
‘‘death’’ genes can augment apoptosis [30].
Table 1
Taxol-induced serine phosphorylation of p66shc
Cells RAW 264.7 A549
Effective
dosage
micromolar
range > 1 AM Taxol;
maximum: f 5–10 AM
nanomolar
range >10 nM Taxol;
maximum: f 50–100 nM
Time course maximum: 30 min maximum: 9–18 h
MEK inhibitors
(U0126,
PD98059)
inhibitory effect on serine/
threonine phosphorylation
of p66sch
(MEK-dependent)
no effect on serine
phosphorylation
of p66shc
(MEK-independent)
Mediated by Taxol only all microtubule
interacting agents
Correlated with TNFa expression PARP cleavage
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The relationship between the structure of Taxol and other
taxanes on induction of TNF-a gene expression and cyto-
toxicity has been studied and it was found that changes in
the structure of Taxol that did not alter cytotoxicity did
prevent the induction of TNF-a [15]. A recent structure–
activity relationship study, using synthetic Taxol analogs to
examine their potencies in inducing nitric oxide and TNF-a,
has shown that the benzoyl group at C-2, the hydroxy group
at C-7, and the acetyl group at C-10 in Taxol are important
sites for the activation of murine macrophages [36]. No
TNFa production was observed using a variety of Taxol
analogs in human blood cells [36].
In general, phosphorylation of tyrosine, serine, and threo-
nine residues in a molecule can generate recognition motifs
for protein–protein interactions and complex formation,
thereby initiating new signaling events. It has been suggested
that the CH1 and CH2 domains of Shc isoforms might be
involved in a network of protein–protein interactions that are
Ras-independent [21]. One example of a protein–protein
interaction that involves p66shc has been demonstrated in
glomerular mesangial cells [26]. In these cells, endothelin-1
induces serine phosphorylation of p66shc and its association
with 14-3-3 proteins. These proteins have been shown to
bind to a variety of signaling molecules, including kinases
and phosphatases, and have been implicated in processes
such as apoptosis and cell cycle control [26].
The MEK inhibitor U0126 inhibits serine phosphoryla-
tion of p66shc in RAW 264.7 cells, probably through a
feedback mechanism. Although the MEK inhibitor U0126
inhibited the mobility shift of p66shc induced by Taxol, two
p66shc bands are seen in samples treated with 10 AM Taxol
plus U0126, suggesting that p66shc is phosphorylated not
only by a MEK-dependent pathway in which ERK1/2
activation is completely suppressed by U0126 (see Fig.
4A), but also by other kinases. In fact, a light p66shc band
also was constantly observed in control cells, suggesting
that p66shc may undergo intrinsic phosphorylation without
Taxol or LPS treatment. In addition, inhibition of the MEK
pathway by U0126 only partially (f 60%) blocked the
Taxol-induced TNFa expression, suggesting that multiple
parallel pathways may be involved in the expression of
TNFa in response to Taxol in RAW 264.7 cells.
We previously have demonstrated that Taxol induces
tyrosine phosphorylation of p52shc and Shc/Grb2 complex
formation in RAW 264.7 cells [28]. However, unlike Taxol-
induced serine phosphorylation of p66shc that can be
blocked by the MEK inhibitor U0126, Taxol-induced Shc/
Grb2 complex formation was not significantly inhibited by
U0126 (data not shown). Therefore, the role of Taxol-
induced tyrosine phosphorylation of p52shc and its coordi-
nation with Taxol-induced serine phosphorylation of p66shc
on TNFa expression, is not clear yet.
In summary, we have determined that the mechanisms
involved in Taxol-induced serine phosphorylation of p66shc
are quite different in A549 and RAW 264.7 cells. All
microtubule interacting agents are capable of mediating this
event in A549 cells. However, in RAW 264.7 cells, only
Taxol can induce p66shc serine/threonine phosphorylation,
indicating that this is a microtubule-independent event in
this cell line.
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